NumFin

Idera Pharmaceuticals, Inc.

Symbol: IDRA

NASDAQ

0.425

USD

Markedspris i dag

  • -97.1145

    P/E-forhold

  • 7.8442

    PEG Ratio

  • 26.50M

    MRK Cap

  • 0.00%

    DIV Udbytte

Idera Pharmaceuticals, Inc. (IDRA) Årsregnskaber

Download
ÅrligKvartalsvis
LineærLog
På diagrammet kan du se standardtallene i dynamik for Idera Pharmaceuticals, Inc. (IDRA). Virksomhedens omsætning viser gennemsnittet af NaN M, som er NaN % gowth. Den gennemsnitlige bruttofortjeneste for hele perioden er NaN M, som er NaN %. Den gennemsnitlige bruttofortjeneste er NaN %. Væksten i nettoindkomst for virksomheden sidste år er NaN %, hvilket svarer til NaN % % i gennemsnit for hele virksomhedens historie.,

ÅrligKvartalsvis
10Y20Y30Y40Y

Balance

Når vi dykker ned i den skattemæssige udvikling for Idera Pharmaceuticals, Inc., ser vi en gennemsnitlig aktivvækst. Det er interessant, at denne rate ligger på , hvilket afspejler både virksomhedens op- og nedture. Når man sammenligner kvartal for kvartal, justeres dette tal til . Et kig tilbage på det seneste år afslører en samlet aktivændring på NaN. Aktionærværdi, som vist ved den samlede egenkapital, er vurderet til NaN i rapporteringsvalutaen. Ændringen fra år til år i dette aspekt er NaN%.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

balance-sheet.row.cash-and-short-term-investments

65.441232.537.7
42.8
71.4
112.6
109
60.2
41.2
29.4
10.1
24.6
34.6
31.7
55.6
23.7
38.2
8.4
14.4
13.7
19.2
31.8
3.5
2.6
5.6
2.2
16.4
5.3

balance-sheet.row.short-term-investments

0004.5
2.8
0
0
28.3
33.6
21.3
3.1
0
0
17.6
6.3
10.4
11.2
13.6
7.4
9.4
6.1
14.6
10.9
2
0
0
0
3.8
0

balance-sheet.row.net-receivables

8.384.200
0
0
0
0
0
0
0
0
0
0
4.5
0.5
0.6
0.4
0.2
0.3
0.2
0.4
0.3
0.3
1.2
1.2
0.5
0
0

balance-sheet.row.inventory

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

5.351.61.53.6
3.5
1.4
4
2
3.1
1.2
0.9
0.2
0.3
1
1
0.9
0.7
0.4
0.5
0.3
0.1
0.2
0.1
0.1
0.1
0.1
1
2.1
0.9

balance-sheet.row.total-current-assets

79.1617.93441.4
46.3
72.8
116.6
111
63.2
42.4
30.3
10.3
24.8
35.6
37.3
57
25
39
9
15
14
19.8
32.2
3.9
3.9
6.9
3.7
18.5
6.2

balance-sheet.row.property-plant-equipment-net

2.270.50.81
1.2
0.2
1.5
1.9
1.7
1.3
0.1
0.2
0.5
0.9
1.4
1.8
2
0.6
0.4
0.4
0.4
0.5
0.1
0.1
6.4
8.8
19.2
15.6
9.1

balance-sheet.row.goodwill

25.6611.100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

201.6771.600
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

227.3382.700
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
0
0
0
27
7.3
6.2
0
0
0
8.5
0
0
0
0
0
0
941.1
0
0
0
0
0
0
1.7

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0.8200.10.1
0.1
0
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.5
0.6
0.7
0.9
0.5
0
0
-940.1
0
6
1.6
0.9
12.1
7.4
2.6

balance-sheet.row.total-non-current-assets

230.4383.20.81
1.2
0.2
1.8
2.2
29
9
6.6
0.5
0.8
1.2
10.4
2.4
2.7
1.5
0.9
0.4
0.4
1.5
0.1
6.1
8
9.6
31.3
23
13.4

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

309.59101.134.942.4
47.5
73
118.4
113.2
92.3
51.4
36.9
10.8
25.6
36.9
47.6
59.4
27.7
40.5
10
15.4
14.4
21.2
32.3
10
11.9
16.5
35.1
41.5
19.6

balance-sheet.row.account-payables

15.525.20.60.3
0.5
1.1
1.3
0.6
1.2
2.5
0.9
1.1
1.2
1.8
1.2
1.3
1.2
1.2
0.5
0.4
0.7
0.8
0.5
1.1
1.6
2.4
8.1
4.1
2.1

balance-sheet.row.short-term-debt

0.920.20.20.2
0.2
0
0.2
0.3
0.3
0.1
0
0
0
0
0
0
0.3
0
0
0
1.3
0
3.4
6
6.1
6.1
7.9
1.3
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

1.420.30.50.8
0.9
0
0
0.2
0.5
0.7
0
0
0
0
0
0
0.9
5
5
0
0
1.3
1.3
9.4
7.8
1.8
53.3
9
1.1

Deferred Revenue Non Current

0000
0
0
0
0.2
1.3
0
0
0
0
0
0.1
12.2
9.9
15249.6
1229.5
523.7
651.2
363.4
26129.7
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

10.19---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

46.81164.16.5
53.9
7.9
8
7.4
4.3
4.5
3.5
3
4.9
1.8
0.9
1.2
1.7
0.9
1.3
1.3
1.1
0.8
-3097.6
1.1
2.5
4.1
11.9
4.3
3.9

balance-sheet.row.total-non-current-liabilities

142.9540.80.5126.5
4.1
0
0.6
0.5
1.9
1
0
0.1
7.5
0.2
0.3
12.4
10.9
20.3
6.3
0.8
0.7
1.7
27.4
9.4
7.8
1.8
53.3
9
1.2

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

2.330.60.80.9
1.1
0
0
0
0
0
0
0
0
0
0
0
0.1
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

206.2162.25.4133.6
58.7
9
10.7
9.9
8.7
8
4.4
4.2
13.6
3.8
14.5
37.2
20
28.3
10.3
2.6
3.9
3.8
32.3
17.5
18
14.3
81.1
18.7
7.2

balance-sheet.row.preferred-stock

55.234.300
0
0
0
0
0
0
11
9.6
5.9
0
0
0
0
0
0
0
0
0
6.4
0
0
0
0
0
0

balance-sheet.row.common-stock

0.1200.10
0
0
0.2
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0.1
0.1
0.1
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-3032.5-758.8-735.5-833.6
-720.9
-664.4
-604.5
-538.5
-500.1
-451.5
-412.9
-394.7
-375.4
-351.6
-333.7
-341.2
-342.7
-329.5
-313
-299.3
-283.9
-261.1
-273.9
-260.2
-253.2
-238.4
-218.7
-149.2
-102.3

balance-sheet.row.accumulated-other-comprehensive-income-loss

-0.02000
-0.8
-0.7
0
0
-0.1
0
0
-3.2
0
0
0
0
0
0
-0.1
0
0
0
-5.3
-5.3
-14.7
-13.8
-11.1
-6.6
-4.2

balance-sheet.row.other-total-stockholders-equity

3053.47736.4764.9742.3
710.5
729
712
641.7
583.7
494.9
434.3
394.8
381.5
384.7
366.8
363.4
350.4
341.7
312.6
312
294.4
278.6
272.7
257.9
261.8
254.5
183.7
178.6
118.9

balance-sheet.row.total-stockholders-equity

76.2711.829.5-91.2
-11.2
64
107.7
103.3
83.6
43.4
32.5
6.6
12
33.1
33.1
22.2
7.7
12.2
-0.3
12.8
10.5
17.4
0
-7.5
-6.1
2.2
-46
22.9
12.4

balance-sheet.row.total-liabilities-and-stockholders-equity

282.487434.942.4
47.5
73
118.4
113.2
92.3
51.4
36.9
10.8
25.6
36.9
47.6
59.4
27.7
40.5
10
15.4
14.4
21.2
32.3
10
11.9
16.5
35.1
41.5
19.6

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

76.2711.829.5-91.2
-11.2
64
107.7
103.3
83.6
43.4
32.5
6.6
12
33.1
33.1
22.2
7.7
12.2
-0.3
12.8
10.5
17.4
0
-7.5
-6.1
2.2
-46
22.9
12.4

balance-sheet.row.total-liabilities-and-total-equity

282.48---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0004.5
2.8
0
0
28.3
60.6
28.6
9.3
0
0
17.6
14.7
10.4
11.2
13.6
7.4
9.4
6.1
15588.5
10.9
2
0
0
0
3.8
1.7

balance-sheet.row.total-debt

2.330.60.80.9
1.1
0
0.2
0.5
0.8
0.9
0
0
0
0
0
0
1.2
5
5
0
1.3
1.3
4.7
15.4
13.9
7.9
61.2
10.3
1.6

balance-sheet.row.net-debt

-63.1-11.5-31.8-32.3
-39
-71.4
-112.4
-80.2
-25.8
-19.1
-26.3
-10.1
-24.6
-17
-25.4
-45.1
-11.4
-19.6
4.1
-5
-6.3
-3.2
-16.2
13.8
11.3
2.2
58.9
-2.3
-3.7

Pengestrømsopgørelse

Det økonomiske landskab for Idera Pharmaceuticals, Inc. har set en bemærkelsesværdig ændring i det frie cash flow i løbet af den sidste periode, hvilket udviser et skift på NaN. Virksomheden udvidede for nylig sin aktiekapital ved at udstede NaN, hvilket markerer en forskel på NaN i forhold til det foregående år. Virksomhedens investeringsaktiviteter resulterede i et nettokasseforbrug på NaN i rapporteringsvalutaen. Dette er en forskydning på NaN fra året før. I samme periode har virksomheden registreret NaN, NaN og NaN, som er væsentlige for forståelsen af virksomhedens investerings- og afdragsstrategier. Virksomhedens finansieringsaktiviteter førte til et nettokasseforbrug på NaN, med en forskel fra år til år på NaN. Desuden afsatte virksomheden NaN til udbetaling af udbytte til sine aktionærer. Samtidig foretog virksomheden andre finansielle manøvrer, kaldet NaN, som også påvirkede pengestrømmen betydeligt i denne periode. Disse komponenter tegner tilsammen et omfattende billede af virksomhedens økonomiske status og strategiske tilgang til likviditetsstyring.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997199619951994

cash-flows.row.net-income

-41.05-23.498.1-112.7
-56.5
-59.9
-66
-38.4
-48.6
-38.6
-18.2
-19.2
-23.8
-18
7.5
1.5
-13.2
-16.5
-13.7
-12.7
-17.2
17
-5.3
-2.9
-10.5
-17.1
-69.5
-46.9
-34.5
-25.6

cash-flows.row.depreciation-and-amortization

0.01000.1
0.1
0.4
0.7
0.7
0.5
0.2
0.1
0.3
0.5
0.5
0.6
0.6
0.3
0.4
0.3
0.3
0.3
0.6
0.2
0.8
2.5
4.3
4.5
2.4
2
1.1

cash-flows.row.deferred-income-tax

-0.27-6.300
0
0
0
0
0
0
0
0
0
0
0
0
-1.6
-924.5
-99.7
-542.7
1297.4
1297.4
-1850.2
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

02.22.53.6
3.8
5.7
10.7
6.8
5.4
4.3
1.4
2.1
2.8
3.7
3.1
0
1.6
924.5
99.7
542.7
-1297.4
-1297.4
1850.2
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-0.860.30.4-1.1
-3.3
1.3
-1
1.9
-1.2
2.5
-0.6
-2.4
0.8
-6.1
-26.9
18.4
-5.1
17.4
2.6
-0.3
0.2
-28.6
11.9
-6.5
-1.3
-1.2
12.3
2.7
0.2
2.3

cash-flows.row.account-receivables

2-2.300
0
0
0
0
0
0
0
0
0
4.5
0
0
-0.2
0
117.2
203.4
-131.4
-131.4
-243.4
0
0
0
0
0
0
0

cash-flows.row.inventory

0000
0
0
0
0
0
0
0
0
0
0.1
0
0
-0.3
0
-58.3
-356.4
-24
-59.6
734.4
0
0
0
0
0
0
0

cash-flows.row.account-payables

-2.742.5-1.8-1.6
-1.1
-0.9
1.7
2
-1.7
2.8
0.1
-2.4
0.2
1.4
0
0
0.9
-251.3
-61.3
139.6
144.9
144.9
-506.4
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

1.7-0.32.10.5
-2.2
2.2
-2.7
0
0.5
-0.3
-0.7
0.1
0.6
-12.2
-26.9
18.4
-5.5
268.8
5
13.2
10.7
17.6
27.3
-6.5
-1.3
-1.2
12.3
2.7
0.2
0

cash-flows.row.other-non-cash-items

9.522.7-125.676.3
11.3
0.6
0.2
0.7
0.9
0.3
0.2
-0.7
0.5
0.3
0
3
2.2
1.2
0.2
-0.6
2.4
0
6.3
0.8
0.7
-8.6
1.5
-0.4
-0.2
0.8

cash-flows.row.net-cash-provided-by-operating-activities

-29.78000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0000
0
-0.1
-0.2
-0.4
-0.7
-1.1
0
0
0
-0.1
-0.1
-0.4
-1.6
-0.1
-0.2
-0.1
-0.1
-0.4
-0.1
0
0
-0.5
-7.5
-8.9
0
0

cash-flows.row.acquisitions-net

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-14080
403.6
-6396.4
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

000-12.2
-44.5
0
0
-2.9
-63.1
-23.6
-9.3
-1
-1
-10.3
-14.8
-23
-50.5
-26.8
-19.9
-18.6
-17.7
-16
-13.7
-2
0
0
0
-7.5
0
0

cash-flows.row.sales-maturities-of-investments

004.510.5
42.1
0
28.3
34.7
30.4
4.1
0
18.6
18.6
7.2
10.4
23.6
53
20.6
21.9
15.2
29.4
10.9
20.2
0
0
0
3.8
0
0
0

cash-flows.row.other-investing-activites

5.485.500
0
0.3
0
0
0
0
0
0.1
0.1
0.1
0.1
0
0
-0.6
0
14080
-403.6
6396.4
0
11.6
0
6.2
0
0.4
-6.6
-5.1

cash-flows.row.net-cash-used-for-investing-activites

5.485.54.5-1.7
-2.4
0.2
28.1
31.4
-33.4
-20.6
-9.3
17.6
17.6
-3.1
-4.3
0.2
0.9
-6.9
1.8
-3.5
11.7
-5.5
6.5
9.6
0
5.7
-3.7
-16
-6.6
-5.1

cash-flows.row.debt-repayment

000-0.2
0
-0.2
-0.3
-0.3
-0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-7.3
-1.6
-0.4
0
0

cash-flows.row.common-stock-issued

000.228.8
15.4
0
53.8
49
80.6
37.1
40.2
0
0
14.1
0
10
1.8
27.9
0.1
15.6
13.1
0.5
0.7
0.2
1.5
6.9
0
55.4
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
-0.1
0
0
0
-5339.5
-5.3
0
0
0
0
0
0
0
41.9
19.8

cash-flows.row.dividends-paid

0000
0
0
0
0
0
-0.8
-1.1
-0.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

-1.58-1.519.30.1
0.1
10.4
5.7
2.2
2.5
9.3
3.5
6
9.1
0.1
0.3
-1.2
1.1
0
4.6
5338.2
0
-0.4
-1
-3
4.1
20.8
46
10.6
-0.8
1.4

cash-flows.row.net-cash-used-provided-by-financing-activities

-1.58-1.519.428.7
15.5
10.2
59.2
50.9
83
45.6
42.7
5.4
9.1
14.2
0.2
8.8
2.9
27.9
4.7
14.3
7.8
0.1
-0.3
-2.8
5.6
20.4
44.4
65.5
41.1
21.2

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
-17.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-25.88-20.5-0.7-6.8
-31.4
-41.5
32
54.1
6.6
-6.3
16.2
-14.5
7.6
-8.5
-19.7
32.6
-12
23.6
-4
-2.6
5.1
-16.4
19.4
-1
-3
3.4
-10.4
7.3
1.9
-5.4

cash-flows.row.cash-at-end-of-period

65.441232.533.2
40
71.4
112.6
80.7
26.6
20
26.3
10.1
24.6
17
25.5
45.2
12.6
24.6
1
5
7.6
4.5
20.9
1.5
2.6
5.6
2.2
12.6
1.9
66.1

cash-flows.row.cash-at-beginning-of-period

91.3132.533.240
71.4
112.9
80.7
26.6
20
26.3
10.1
24.6
17
25.5
45.2
12.6
24.6
1
5
7.6
2.5
20.9
1.5
2.6
5.6
2.2
12.6
5.3
0
71.4

cash-flows.row.operating-cash-flow

-29.78-24.5-24.6-33.8
-44.5
-51.9
-55.3
-28.2
-43
-31.3
-17.1
-19.9
-19.2
-19.6
-15.6
23.6
-15.8
2.6
-10.5
-13.3
-14.4
-11
13.1
-7.8
-8.6
-22.7
-51.1
-42.1
-32.6
-21.4

cash-flows.row.capital-expenditure

0000
0
-0.1
-0.2
-0.4
-0.7
-1.1
0
0
0
-0.1
-0.1
-0.4
-1.6
-0.1
-0.2
-0.1
-0.1
-0.4
-0.1
0
0
-0.5
-7.5
-8.9
0
0

cash-flows.row.free-cash-flow

-29.78-24.5-24.6-33.8
-44.5
-52
-55.5
-28.6
-43.7
-32.4
-17.1
-19.9
-19.2
-19.6
-15.7
23.2
-17.4
2.5
-10.8
-13.4
-14.4
-11.4
13
-7.8
-8.6
-23.1
-58.7
-51
-32.6
-21.4

Resultatopgørelse række

Idera Pharmaceuticals, Inc.s omsætning oplevede en ændring på NaN% sammenlignet med den foregående periode. Bruttofortjenesten for IDRA rapporteres til at være NaN. Virksomhedens driftsomkostninger er NaN og viser en ændring på NaN% fra sidste år. Udgifterne til afskrivninger er NaN, hvilket er en ændring på NaN% fra sidste regnskabsperiode. Driftsudgifterne rapporteres at være NaN, hvilket viser en NaN% ændring fra år til år. Salgs- og marketingomkostninger er NaN, hvilket er en ændring på NaN% sammenlignet med året før. EBITDA baseret på de seneste tal er NaN, hvilket repræsenterer en NaN% vækst i forhold til året før. Driftsindtægterne er NaN, som viser en ændring på NaN% sammenlignet med året før. Ændringen i nettoindkomsten er NaN%. Nettoindkomsten for det sidste år var NaN.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997199619951994

income-statement-row.row.total-revenue

0000
1.4
0.7
0.9
16.2
0.2
0.1
0
0.1
0.1
16.1
34.5
26.4
8
2.4
2.5
0.9
0.9
30.3
0.8
0.3
7
4.5
3.9
4
1.4
1.2

income-statement-row.row.cost-of-revenue

5.67000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.8
-2.5
0
0
0
0
0

income-statement-row.row.gross-profit

-5.67000
1.4
0.7
0.9
16.2
0.2
0.1
0
0.1
0.1
16.1
34.5
26.4
8
2.4
2.5
0.9
0.9
30.3
0.8
1.1
9.5
4.5
3.9
4
1.4
1.2

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

15.4---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

14.73---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

28.558.31.30
0.2
4.4
0
0
0
0
0
0
0
0
0
0
0
0
99.7
0
542.7
6719.5
-4.1
0.8
2.5
0
0
0
0
0

income-statement-row.row.operating-expenses

51.5832.727.736.7
47.3
57.3
67.4
55
49.1
38.8
18.2
20
25.9
34.1
27.1
25.9
22.7
19
16.3
13.9
18.3
13.6
7.4
7.6
19.3
27.5
57.9
50.7
35.8
26.7

income-statement-row.row.cost-and-expenses

57.2532.727.736.7
47.3
57.3
67.4
55
49.1
38.8
18.2
20
25.9
34.1
27.1
25.9
22.7
19
16.3
13.9
18.3
13.6
7.4
6.8
16.8
27.5
57.9
50.7
35.8
26.7

income-statement-row.row.interest-income

0000.2
1.1
1.1
0.6
0.4
0.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0.6
0.2
0
0
0
0
0
0

income-statement-row.row.interest-expense

0.020.200
0
0
0.1
0.1
0.1
0
0
0
0
0
0
0.1
0.1
0.4
0.3
0
0.1
0.2
1.3
2.2
0
0
0
0
-0.2
-0.1

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-0.02-0.20-76
-10.4
1.1
0.5
0.4
0.3
0.1
-0.1
0.7
2.1
0
0.1
1
1.5
0
0.1
0.2
0.2
-0.2
0.5
0.1
0
0
-11
0
-0.2
-0.1

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

28.558.31.30
0.2
4.4
0
0
0
0
0
0
0
0
0
0
0
0
99.7
0
542.7
6719.5
-4.1
0.8
2.5
0
0
0
0
0

income-statement-row.row.total-operating-expenses

-0.02-0.20-76
-10.4
1.1
0.5
0.4
0.3
0.1
-0.1
0.7
2.1
0
0.1
1
1.5
0
0.1
0.2
0.2
-0.2
0.5
0.1
0
0
-11
0
-0.2
-0.1

income-statement-row.row.interest-expense

0.020.200
0
0
0.1
0.1
0.1
0
0
0
0
0
0
0.1
0.1
0.4
0.3
0
0.1
0.2
1.3
2.2
0
0
0
0
-0.2
-0.1

income-statement-row.row.depreciation-and-amortization

1.711.700.1
0.1
0.4
0.7
0.7
0.5
0.2
0.1
0.3
0.5
0.5
0.6
0.6
0.3
0.4
0.3
0.3
0.3
0.6
0.2
0.8
2.5
4.3
4.5
2.4
2
1.1

income-statement-row.row.ebitda-caps

-45.91---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-47.62-29.598.1-36.7
-46.1
-61
-66.5
-38.8
-48.8
-38.8
-18.2
-19.9
-25.9
-18
7.4
0.5
-14.7
-16.6
-13.8
-12.9
-17.4
16.6
-6.6
-6.5
-9.8
-23
-64.9
-46.7
-34.4
-25.5

income-statement-row.row.income-before-tax

-47.64-29.798.1-112.7
-56.5
-59.9
-66
-38.4
-48.6
-38.6
-18.2
-19.2
-23.8
-18
7.5
1.5
-13.2
-16.5
-13.7
-12.7
-17.2
16.5
-6.1
-6.5
0
0
-75.9
0
-34.5
-25.6

income-statement-row.row.income-tax-expense

-6.59-6.30-76
-10.4
1.1
0.5
0.4
0.4
0.1
-0.1
0.7
2.1
0
0
0
1.7
0
0.4
0.2
0.3
-0.5
0.5
2.2
0
0
-11
0
-0.3
-0.1

income-statement-row.row.net-income

-41.05-23.498.1-112.7
-56.5
-59.9
-66
-38.4
-48.6
-38.6
-18.2
-19.2
-23.8
-18
7.5
1.5
-13.2
-16.5
-13.7
-12.7
-17.2
17
-5.3
-2.9
-10.5
-17.1
-69.5
-46.9
-34.5
-25.6
Lignende aktier
Du er måske også interesseret i:
MRVI
Maravai LifeSciences Holdings, Inc..
7.7 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.0361 USD
NASDAQ
T5O.DE
CytoTools AG.
0.488 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.09 NOK
OSL
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ
SPHRF
Starpharma Holdings Limited.
0.0774 USD
PNK

Ofte stillede spørgsmål

Hvad er Idera Pharmaceuticals, Inc. (IDRA) samlede aktiver?

Idera Pharmaceuticals, Inc. (IDRA) samlede aktiver er 101107000.000.

Hvad er virksomhedens årlige omsætning?

Den årlige omsætning er -49000.000.

Hvad er virksomhedens profitmargin?

Virksomhedens profitmargin er 58.878.

Hvad er virksomhedens frie pengestrøm?

Det frie cash flow er -0.003.

Hvad er virksomhedens nettoprofitmargin?

Nettofortjenstmargenen er 665.265.

Hvad er firmaets samlede omsætning?

Den samlede omsætning er 680.245.

Hvad er Idera Pharmaceuticals, Inc. (IDRA) nettoresultat (nettoindkomst)?

Nettoresultatet (nettoindkomsten) er -23360000.000.

Hvad er virksomhedens samlede gæld?

Den samlede gæld er 560000.000.

Hvad er tallet for driftsudgifter?

Driftsudgifterne er 32680000.000.

Hvad er firmaets likviditet?

Virksomhedens likviditet er 2118000.000.